Koninklijke Philips N.V.
PHGHealthcareNASDAQMedical Devices · Last scanned Jul 18, 2026
Scan Results
Daily timeframeKoninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. Valued at $26.19B, PHG is a large-cap name in its sector. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.
Market Cap
$26.19B
Beta
0.92
P/E (TTM)
24.06
P/E (Fwd)
13.33
EPS (TTM)
$1.12
EPS (Fwd)
$2.02
ROE
8.4%
ROA
3.5%
Cash
$2.59B
Total Debt
$8.10B
Free CF
$1.52B
52W Change
9.6%
Annual Financials
Cash vs Debt
Koninklijke Philips N.V. carries $8.10B in total debt against $2.59B in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.52B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 8.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $17.16B (2021) to $17.83B (2025).
Investors considering Koninklijke Philips N.V. should weigh the typical risks associated with PHG's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing PHG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.